请选择 进入手机版 | 继续访问电脑版

Lilly, Boehringer score FDA backing for Lantus copy, but patent fight awaits

摘要:  Lilly, Boehringer score FDA backing for Lantus copy, but patent fight awaitsAugust 19, 2014 | By Tracy StatonEli Lilly ($LLY) nabbed tentative FDA approval for its knockoff version of Sanofi's diabete ...

Lilly, Boehringer score FDA backing for Lantus copy, but patent fight awaits


August 19, 2014 | By Tracy Staton


Eli Lilly ($LLY) nabbed tentative FDA approval for its knockoff version of Sanofi's diabetes blockbuster Lantus, but the company won't be able to sell its copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi ($SNY). Lilly and its partner Boehringer Ingelheim have to duke it out in patent court with the French drugmaker, which sued for infringement earlier this year.

欢迎点击上方关注按钮,关注我们的公众号

关注我们的了解行业最新资讯

官网手机版

微信公众号

返回顶部